Ocuphire Pharma reports Q4 2022 net income $33.9M, full-year net income $17.9M; cash $42.6M

Opus Genetics, Inc.

Net income $17.9M for 2022 vs net loss $56.7M in 2021; diluted EPS $0.87.
Revenue $39.9M from Nyxol license agreement with Viatris (upfront $35M).
Cash $42.6M, no debt, runway into 2025.
PDUFA date Sept 28, 2023 for Nyxol in reversal of mydriasis; $10M milestone upon approval.
APX3330 ZETA-1 trial achieved statistical significance on key endpoint; End-of-Phase 2 meeting planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Opus Genetics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

View on SEC.gov

31 earnings releases filed in the last 30 days. Browse all earnings releases →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-014674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.